- $7.38m
- $12.72m
- $0.05m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:43 PM
Brief: HCW Biologics Regains Compliance With All Continued Listing Rules For Nasdaq Per Nasdaq Determination Letter
Brief: Hcw Biologics And Wy Biotech Announce Closing Of First Round Of Financing For Newly Formed Joint Venture Trimmune
Brief: Hcw Biologics Announces Warrant Inducement Agreement
Brief: Hcw Biologics Announces Initiation Of First-In-Human Clinical Trial To Evaluate Hcw9302 In An Autoimmune Disease
Brief: HCW Biologics Says Substantial Doubt Exists Regarding Ability To Continue As Going Concern For At Least 12 Months
David Di Pilla's HCW fund surges on partially deferring Healthscope rental payments
Brief: HCW Biologics Announces 1-For-40 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Talen Energy, Gold miners, Stratasys
U.S. STOCKS ON THE MOVE-HCW Biologics, Talen Energy
HCW Biologics rises as US FDA approves trial for hair loss treatment
Brief: Hcw Biologics Prices $6.9 Mln Registered Direct Offering And Concurrent Private Placement At $1.03 Per Share
Brief: HWC Biologics Due To Default Issue, Concluded Financial Statements As Of & For Year Ended Dec 31, 2023 Should Be Restated & No Longer Be Relied Upon
Brief: HCW Biologics Exercised Right To Terminate Credit Agreement With Prime Capital Ventures
Brief: Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Brief: HCW Biologics - On Aug 29, Granted U.S. Patent Which Contains Claims For Method Of Promoting Activation, Proliferation Of Natural Killer Cells
Brief: HCW Biologics Granted Third Fundamental Patent
Brief: Hcw Biologics Reports Q1 C2023 Financial Results And Recent Business Highlights
Brief: HCW Biologics Secures $26.25 Mln Non-Dilutive Financing